Jan 4 |
Sutro Biopharma Highlights Potential Multi-Cancer Opportunity for Luvelta, a FolRα-targeting ADC
|
Dec 29 |
Sutro: Luveltamab Data At ESMO Signifies Continued ADC Advancement
|
Dec 18 |
Sutro Biopharma, Inc.'s (NASDAQ:STRO) Share Price Boosted 48% But Its Business Prospects Need A Lift Too
|
Dec 14 |
Sutro Biopharma to Host Investor Webcast Highlighting Potential Multi-Cancer Opportunity for Luvelta, a FolRα-targeted ADC, on January 4, 2024
|
Dec 11 |
Sutro Biopharma Announces New Positive Data from the Compassionate Use of Luveltamab Tazevibulin (luvelta) in Pediatric Patients with Relapsed/Refractory CBF/GLIS Presented at ASH 2023
|
Dec 4 |
Sutro Biopharma to Participate in the JMP Securities Hematology and Oncology Summit
|
Nov 21 |
Sutro Biopharma appoints Chung as its COO
|
Nov 21 |
Sutro Biopharma Promotes Jane Chung to President and Chief Operating Officer
|
Nov 13 |
Sutro Biopharma GAAP EPS of -$0.81, revenue of $16.9M
|
Nov 13 |
Sutro Biopharma files for $300M mixed shelf
|